Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) EPS (Basic) (2022 - 2025)

Corvus Pharmaceuticals has reported EPS (Basic) over the past 4 years, most recently at -$0.15 for Q4 2025.

  • Quarterly results put EPS (Basic) at -$0.15 for Q4 2025, up 6.25% from a year ago — trailing twelve months through Dec 2025 was -$0.16 (up 83.16% YoY), and the annual figure for FY2025 was -$0.19, up 81.37%.
  • EPS (Basic) for Q4 2025 was -$0.15 at Corvus Pharmaceuticals, down from -$0.12 in the prior quarter.
  • Over the last five years, EPS (Basic) for CRVS hit a ceiling of $0.21 in Q1 2025 and a floor of -$0.6 in Q3 2024.
  • Median EPS (Basic) over the past 4 years was -$0.15 (2025), compared with a mean of -$0.16.
  • Biggest five-year swings in EPS (Basic): plummeted 400.0% in 2024 and later skyrocketed 275.0% in 2025.
  • Corvus Pharmaceuticals' EPS (Basic) stood at -$0.21 in 2022, then surged by 38.1% to -$0.13 in 2023, then dropped by 23.08% to -$0.16 in 2024, then grew by 6.25% to -$0.15 in 2025.
  • The last three reported values for EPS (Basic) were -$0.15 (Q4 2025), -$0.12 (Q3 2025), and -$0.1 (Q2 2025) per Business Quant data.